A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

• Status: RECRUITING
• Trial end date: 2029-01-01

Summary

The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).

• Phase: PHASE2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Incyte Corporation
• Treatments: Cyclophosphamide; Mycophenolic Acid; ruxolitinib; Tacrolimus